5 results match your criteria: "University of Nebraska Medical Center and Methodist Hospital[Affiliation]"
Am J Surg
December 2004
Department of Surgery, University of Nebraska Medical Center and Methodist Hospital, 8111 Dodge St., Suite 220, Omaha, NE 68114, USA.
Background: Aortic aneurysms represent a serious and common condition. Current therapies are based on mechanical treatment. With increased knowledge of the biochemical mechanisms responsible for aneurysm expansion, it may be possible to prevent the growth of small aneurysms.
View Article and Find Full Text PDFArch Otolaryngol Head Neck Surg
January 2003
Department of Otolaryngology, University of Nebraska Medical Center and Methodist Hospital Cancer Center, 8303 Dodge St, Omaha, NE 68114, USA.
Background: Iatrogenic facial nerve paralysis is a devastating surgical complication that occasionally results in litigation.
Objective: To analyze litigation trends to better understand the causes and outcomes of suits involving facial nerve paralysis to prevent future litigation and improve physician education.
Design: Retrospective review.
Vasc Endovascular Surg
May 2002
University of Nebraska Medical Center and Methodist Hospital, Omaha, NE 68114, USA.
Blue toe syndrome is a manifestation of distal embolization associated with significant pain and risk of tissue loss. The recommended treatment options for this problem include endarterectomy or bypass with exclusion of the source of emboli. Although focal arterial stenosis can be effectively treated with angioplasty,it is unclear whether performing angioplasty in a lesion suspected of causing distal embolization might actually worsen the condition or what long-term effects this would have in preventing future embolization.
View Article and Find Full Text PDFHead Neck
March 1998
Department of Otolaryngology-Head and Neck Surgery, University of Nebraska Medical Center and Methodist Hospital, Omaha 68198-1225, USA.
Background: Deletion of 9p21 is a common event in many human tumors, including head and neck squamous cell carcinoma (HNSCC). The gene CDKN2, which encodes the protein p16, a cyclin-dependent kinase-4 inhibitor, maps to 9p21. The role of CDKN2 as the tumor suppressor gene in these neoplasms is unclear.
View Article and Find Full Text PDF